Oncology Conference update

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Prof. Mark Socinski

Prof. Mark Socinski
Publication Date

Jun 2024

download Downloadable resources

Professor Mark Socinski joins us live from ASCO 2024 to share his views on the lung cancer data emerging from the conference.

 

In this short video update, he shares his insights on data from the LAURA and ADRIATIC trials and what they could mean for clinical practice in lung cancer management.

 

ASCO 2024 selected lung cancer abstracts

  • Osimertinib after definitive chemoradiotherapy in patients with unresectable stage 3 EGFRm NSCLC: Primary results of the phase 3 LAURA study.
    Ramalingam S, et al.
    Abstract LBA4, ASCO 2024

 

  • ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
    Spigel D, et al.
    Abstract LBA5, ASCO 2024

 

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Beigene, BMS, Cullinan, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis, OncoC4, Regeneron, Spectrum, Summit
Programme summary
  • clock Duration 4 MIN
  • clock Language(s) flag
Watch the video now
Other episodes of this series
ASCO 2024 lung cancer highlights

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

 Current Episode
ASCO 2024 breast cancer highlights

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?
ASCO 2024 HCC highlights

ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?
ASCO 2024 upper GI cancer highlights

ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024
Share this programme
x-twitter
Supporter Acknowledgement
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

animated-video Animated Video
Oncology 
Managing ADC toxicities in HER2+ metastatic breast cancer

Spotlight on nausea and vomiting

Experts
Dr Sara Tolaney
Endorsed by
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Aug 2025
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca.
Oncology 
The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Experts
Prof. Chiara Cremolini
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2025
GI CONNECT GI NURSES CONNECT PRECISION ONCOLOGY CONNECT
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
publication Scientific Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock MIN
  • calendar Jun 2025
PRECISION ONCOLOGY CONNECT SARCOMA CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning - Video, slides and more

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
Explore all programmes